BridgeBio reports second late-stage rare disease drug success, establishing new treatment potential for endocrine disorder ...

Adolescents and young adults with preexisting autoimmune disease are more likely to develop type 1 diabetes than those ...

From the "pot-bellied" appearance to the flaws in the LDDST, Cushing's disease remains one of our most complex endocrine ...

Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...

The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...

The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.

Among postmenopausal women, hormone therapy (HT) use is associated with an increased incidence and risk for developing autoimmune disease.

Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are associated with a reduced risk for autoimmune rheumatic diseases.

The obesity rate for adults in the U.S. dropped to 37% in 2025 after peaking at 39.9% in 2022, but diabetes has reached an ...

The company reported its second late-stage study success, this time with a drug that could become a new treatment standard ...

Attendees can take advantage of free health screenings, learn practical tips for diabetes management, and connect directly ...

Lipid biomarkers, including common measures such as cholesterol and triglycerides as well as newer indicators like lipoproteins, apolipoproteins, and ...